Table 1.
Cohort Baseline Characteristics by Treatment Arm (N = 234)
| Characteristic | Atazanavir/Ritonavir (n = 68) |
Raltegravir (n = 82) |
Darunavir/Ritonavir (n = 84) |
|---|---|---|---|
| Age | 38 (31–44) | 36 (27–45) | 36 (28–47) |
| Male sex, % | 93 | 89 | 88 |
| Race/ethnicity, % | |||
| White | 51 | 44 | 49 |
| Black | 31 | 28 | 29 |
| Hispanic | 16 | 20 | 21 |
| Current smoking, % | 32 | 34 | 32 |
| CD4+ count, cells/µL | 294 (180–461) | 347 (246–450) | 337 (172–424) |
| HIV-1 RNA, log10 copies/mL | 4.76 (4.03–5.15) | 4.48 (3.96–4.94) | 4.62 (3.98–4.95) |
| Weight, kg | 82 (71–90) | 78 (68–89) | 77 (65–84) |
| BMI, kg/m2 | 26 (23–29) | 25 (22–28) | 24 (22–27) |
| Limb fat, kg | 8.6 (6.4–11.2) | 7.3 (5.2–11.5) | 7.9 (5.1–10.0) |
| Trunk fat, kg | 9.6 (6.8–12.9) | 9.9 (6.1–13.3) | 9.0 (5.9–11.9) |
| SAT, cm2 | 222.2 (138.0–308.3) | 213.2 (128.3–291.5) | 181.3 (117.4–266.4) |
| VAT, cm2 | 76.4 (41.2–109.2) | 78.0 (41.6–111.9) | 67.0 (38.6–104.8) |
| Lean body mass, kg | 59.1 (51.4–64.3) | 54.8 (49.3–61.0) | 55.1 (46.7–59.9) |
| Leptin, log10 pg/mL | 3.71 (3.33–3.95) | 3.61 (3.20–3.91) | 3.53 (3.16–3.87) |
| Adiponectin, log10 ng/mL | 3.87 (3.74–4.01) | 3.91 (3.74–4.11) | 3.91 (3.77–4.06) |
Data are presented as median (IQR) unless otherwise indicated.
Abbreviations: BMI, body mass index; HIV-1, human immunodeficiency virus; IQR, interquartile range; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.